SPTX Stock — Seaport Therapeutics Inc.: Cash, EV, Pipeline

Share price

$21.39

Market cap

$1,145.0M

Cash

$273.3M

Enterprise value

$871.7M

Balance sheet

Cash	$273.3M
Debt	$0.0M
Net cash	$273.3M
Enterprise value	$871.7M
Basic shares	53.5M shares
Fully diluted shares	65.8M shares
Fully diluted market cap	$1,406.7M
Cash per share	$5.11

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SPTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24	SPT-300	Phase 2	Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress	—
Jun 12 - Jul 24	SPT-300	Phase 2	Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

GlyphAllo

Phase 2 · Active Modality: Glyphed oral prodrug of allopregnanolone

Aliases Glyph Allopregnanolone

Target GABA-A

Partnerships Monash University (license agreement)

Indications

major depressive disorder with or without anxious distress (Stage not disclosed)

Catalysts

— None
— None

Status note Lead product candidate. Phase 2b BUOY-1 trial in MDD with or without anxious distress initiated; Phase 1 driving simulation trial ongoing.

GlyphAgo

Phase 1 · Active Modality: Glyphed oral prodrug of agomelatine

Aliases Glyph Agomelatine

Target MT1/MT2 + 5-HT2C

Partnerships Monash University (license agreement)

Indications

generalized anxiety disorder with sleep disturbance (Stage not disclosed)
generalized anxiety disorder (Stage not disclosed)

Catalysts

— None
— None

Status note Second product candidate. Topline data from the Phase 1 SAD, crossover and MAD portions reported in April and June 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SPT-300
Lead indication	Major Depressive Disorder (MDD)
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07065240	Phase 2	Recruiting	Sponsor	Seaport Therapeutics	—	Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress	—
NCT07161700	Phase 2	Enrolling by invitation	Sponsor	Seaport Therapeutics	—	Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Seaport Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	500,000	+500,000	0.40%	2026-08-14
ADAR1 Capital Management	26,000	+26,000	0.03%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

SPTX — Seaport Therapeutics Inc.